Nascent Biotech, Inc. (NBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0003
-0.0003 (-50.00%)
Aug 22, 2025, 4:00 PM EDT
Nascent Biotech Company Description
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.
It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
Contact Details
Address: 631 US Hwy 1 North Palm Beach, Nevada 33408 United States | |
| Phone | 612 961 5656 |
| Website | nascentbiotech.com |
Stock Details
| Ticker Symbol | NBIO |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| ISIN Number | US63108Q1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sean Carrick | President, Chief Executive Officer, Secretary and Director |
| Lowell Holden | Chief Financial Officer, Chief Accounting Officer and Director |
| Dr. Mark C. Glassy Ph.D. | Founder |
| Dr. Navpaul Singh M.D. | Chief Medical Consultant |